Sources/Clones
Accurate (TAU2, polyclonal), Accurate/Sigma, Biodesign (TAU2), Biosource (AT8, BT2, HT7), Calbiochem, Chemicon, Dako (polyclonal), Labvision Corp (TAU5), Pharmingen (TAU2.1), Sigma (TAU2, polyclonal) and Zymed (T14, T46).
Fixation/Preparation
Most of the antibodies are immunoreactive in fixed paraffin-embedded sections.
Background
The major components of the neuronal cytoskeleton area and b tubulin, the microfilament-associated proteins (MAPs), neurofilaments and actin. Tau is a neuronal microtubule-associated protein which is the major antigenic component of neurofibrillary tangles and senile plaques in Alzheimer's disease (Joachim et al, 1987). Comparison of tau-immunoreactive lesions in three relatively uncommon neurodegenerative diseases, namely supranuclear palsy, Pick's disease and corticobasal degeneration, demonstrated unexpected pathological similarities, but also fundamental differences between these disorders (Feany & Dickson, 1996).
Tau2 was produced using bovine MAP as immunogen. It reacts exclusively with the chemically heterogenous tau in both the phosphorylated and non-phosphorylated forms. Tau2 does not react with other MAPs or with tubulin and localizes along microtubules in axons, dendrites, somata and astrocytes and on ribosomes. Tau2 crossreacts with bovine, monkey and chicken tissue. A variety of antibodies to phosphorylated neurofilament proteins have been shown to crossreact with phosphorylated epitopes of tau (Perry et al, 1985; Cork et al, 1986).
Applications
Applications of tau are mainly in the field of neuropathological research in neurodegenerative disorders. In the diagnostic setting, conventional silver impregnation stains such as Bielchowsky or Bodian are used for the demonstration of neurofibrillary tangles. These can now also be detected with antibodies to phosphorylated tau epitopes and ubiquitin.
Comments
None
References
•Cork LC, Sternberger NH, Sternberger LA, et al 1986. Phosphorylated neurofilament antigens in neurofibrillary tangles in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology 45: 56-64.
•Feany MB, Dickson DW 1996. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Annals of Neurology 40: 139-148.
•Joachim CL, Morris JH, Kosik KS, Selkoe DJ 1987. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Annals of Neurology 22: 514-520.
•Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P 1985. Paired helical filaments from Alzheimer's disease patients contain cytoskeletal components. Proceedings of the National Academy of Sciences USA 82: 3916-3920.
Bibliografia
Manual of diagnostic antibodies for immunohistology / Anthony S.-Y. Leong, Kumarasen Cooper, F. Joel W.-M. Leong.
Accurate (TAU2, polyclonal), Accurate/Sigma, Biodesign (TAU2), Biosource (AT8, BT2, HT7), Calbiochem, Chemicon, Dako (polyclonal), Labvision Corp (TAU5), Pharmingen (TAU2.1), Sigma (TAU2, polyclonal) and Zymed (T14, T46).
Fixation/Preparation
Most of the antibodies are immunoreactive in fixed paraffin-embedded sections.
Background
The major components of the neuronal cytoskeleton area and b tubulin, the microfilament-associated proteins (MAPs), neurofilaments and actin. Tau is a neuronal microtubule-associated protein which is the major antigenic component of neurofibrillary tangles and senile plaques in Alzheimer's disease (Joachim et al, 1987). Comparison of tau-immunoreactive lesions in three relatively uncommon neurodegenerative diseases, namely supranuclear palsy, Pick's disease and corticobasal degeneration, demonstrated unexpected pathological similarities, but also fundamental differences between these disorders (Feany & Dickson, 1996).
Tau2 was produced using bovine MAP as immunogen. It reacts exclusively with the chemically heterogenous tau in both the phosphorylated and non-phosphorylated forms. Tau2 does not react with other MAPs or with tubulin and localizes along microtubules in axons, dendrites, somata and astrocytes and on ribosomes. Tau2 crossreacts with bovine, monkey and chicken tissue. A variety of antibodies to phosphorylated neurofilament proteins have been shown to crossreact with phosphorylated epitopes of tau (Perry et al, 1985; Cork et al, 1986).
Applications
Applications of tau are mainly in the field of neuropathological research in neurodegenerative disorders. In the diagnostic setting, conventional silver impregnation stains such as Bielchowsky or Bodian are used for the demonstration of neurofibrillary tangles. These can now also be detected with antibodies to phosphorylated tau epitopes and ubiquitin.
Comments
None
References
•Cork LC, Sternberger NH, Sternberger LA, et al 1986. Phosphorylated neurofilament antigens in neurofibrillary tangles in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology 45: 56-64.
•Feany MB, Dickson DW 1996. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Annals of Neurology 40: 139-148.
•Joachim CL, Morris JH, Kosik KS, Selkoe DJ 1987. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Annals of Neurology 22: 514-520.
•Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P 1985. Paired helical filaments from Alzheimer's disease patients contain cytoskeletal components. Proceedings of the National Academy of Sciences USA 82: 3916-3920.
Bibliografia
Manual of diagnostic antibodies for immunohistology / Anthony S.-Y. Leong, Kumarasen Cooper, F. Joel W.-M. Leong.
